Companies › Tanabe Pharma
4 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 3; Oncology, Immunology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dersimelagon (MT-7117) Melanocortin receptor 1 agonist | MC1R | Phase 3 | EPP | Dec 2027 |
| Inebilizumab (MT-0551) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Systemic Sclerosis | – |
| Loncastuximab Tesirine (MT-2111) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 1 | Diffuse Large B-Cell Lymphoma | Aug 2028 |
| MT-4561 | – | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05198557 | Inebilizumab (MT-0551) | Phase 3 | Systemic Sclerosis | Immunology | Jul 2025 |
| NCT05005975 | Dersimelagon (MT-7117) | Phase 3 | EPP | Immunology | Dec 2027 |
| NCT05658562 | Loncastuximab Tesirine (MT-2111) | Phase 1 | Diffuse Large B-Cell Lymphoma | Oncology | Aug 2028 |
| NCT06943521 | MT-4561 | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Oncology | Aug 2028 |
Antengene Biologics Beijing Mabworks Biotech Taizhou Mabtech Pharmaceutical Ganzhou Hemay Pharmaceutical Tavotek Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.